Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 188

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 4A
Chunk 188
---
 Our operations to date have been limited to organizing and staffing our
company, business planning, raising capital, developing our technology, acquiring and building our intellectual property portfolio and
conducting research and development activities, including pre-clinical studies and clinical trials, for our Alpha DaRT technology. We
do not have any products approved for sale in the United States and have not generated any revenue from product sales. To date, we have
funded our operations primarily through private placements of ordinary and convertible preferred shares and funding from government contracts.
From inception through December 31, 2024, we have raised an aggregate of $188,227 to fund our operations, of which $179,466 were gross
proceeds from the issuance of our shares and $8,761 were gross proceeds from government grants. We have incurred significant net operating
losses in every year since our inception and expect to continue to incur significant expenses and increasing operating losses for the
foreseeable future. Our net losses may fluctuate significantly from quarter to quarter and year to year and could be substantial. Our
net losses were $29,157 and $31,750 for the years ended December 31, 2023 and December 31, 2024, respectively. As of December 31, 2024,
we had an accumulated deficit of $147,509. We anticipate that our expenses will increase significantly as we:

  conduct additional clinical           

  continue to discover and develop  

  construct manufacturing facilities                                                                                                        
  and supply chain capabilities in multiple geographies of sufficient capacity to provide commercial quantities of our Alpha DaRT products  
  and any other product candidates for which we may obtain marketing approval;                                                              
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  seek regulatory and marketing                                                                                                 

  develop and execute launch strategies,                                                                                                  
  and establish a sales, marketing and distribution infrastructure to commercialize our Alpha DaRT technology and any other products for  
  which we may obtain regulatory approval in geographies in which we plan to commercialize our products ourselves;                        
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  maintain, expand and protect          

  hire additional staff, including                                                                                     

  add clinical, scientific, operational,                                                                                                

We do not expect to generate
revenue from product sales unless and until we successfully complete clinical development and obtain further regulatory approvals for
our Alpha DaRT technology